Gefurulimab
Based on 1 Customer Validation
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 97.88%
- CAS No.: 2456407-94-4
- 분자량:28.17 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
VH-VH'
Human
C5 (complement 5, C5a anaphylatoxin)
Gefurulimab binds specifically and with high affinity to human and cynomolgus monkey C5 and serum albumin; its affinity for C5 exhibits pH-dependent changes, whereas its affinity for HSA shows little pH dependence, and it can bind hC5 and HSA simultaneously[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH'
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2456407-94-4
-
Appearance Liquid
-
분자량 28.17 kDa
-
Color Colorless to light yellow
-
SMILES
[Gefurulimab]
-
Synonyms
ALXN-1720
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sandra Rayego-Mateos, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022 Dec 5:S0085-2538(22)01017-1. [Content Brief]
[2]. Mullin M, et al. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions. MAbs. 2024 Jan-Dec;16(1):2341443. [Content Brief]
[3]. Miwa T, et al. Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases. Annu Rev Med. 2024 Jan 29;75:189-204. [Content Brief]
[4]. Jindal S, et al. Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. Mol Immunol. 2024;165:29-41. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gefurulimab Related Classifications
HY-P99638 Related Classifications
Powered by Bioz